Navigation Links
Pharmaxis Closes Share Purchase Plan
Date:11/18/2007

SYDNEY, Australia, Nov. 18 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS, Nasdaq: PXSL) today announced it had raised $11.7 million from its Share Purchase Plan which closed on 9 November 2007. Shareholders of the company were given the opportunity to purchase up to $5,000 worth of shares each at the $3.90 price paid by institutional investors in the recent placement.

A total of 2,496 shareholders participated in the plan under which the company will issue approximately 3 million new shares and receive cash of approximately $11.7 million.

Dr Alan Robertson, Chief Executive Officer of Pharmaxis said, "We are very encouraged with the level of support from our shareholders. Approximately half participated in the plan, and the average investment was over $4,600."

Shares will be issued today, 16th November 2007, and are expected to be listed on the Australian Securities Exchange on 19 November 2007. Holding statements will be posted on or about 19 November 2007.

About Pharmaxis

Pharmaxis (ACN 082 811 630) is a pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders. Its development pipeline of products include, Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD) and PXS64 for the treatment of multiple sclerosis.

Founded in 1998, Pharmaxis is listed on the Australian Stock Exchange (symbol PXS), and on NASDAQ Global Market (symbol PXSL). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to http://www.pharmaxis.com.au or contact Jane Sugden, Investor Relations +61 2 9454 7230.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statement
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Phase III Trial Finds Pharmaxis Bronchitol Effective
2. Pharmaxis Announces Placement of $50 Million and Share Purchase Plan
3. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
4. Genmab Discloses Target and Development Plans for HuMax-Inflam
5. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
6. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
7. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
8. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
9. BioVex Closes Second Round of Series E Financing
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 DNA vaccine ... progress in its development of JRC-LAMP-vax, an innovative and ... pollen. Phase IC studies began this month in Hawaii, ... hay fever. , The Japanese red cedar releases pollen ... in Japan. Mountain Cedar pollen wreaks similar havoc in ...
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
(Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
(Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
... -- PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that its financial ... released on Thursday, May 14, 2009.PharmAthene management will be ... 2009 financial results. The call is scheduled to ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced its financial ... a net loss for the first quarter of 2009 of $10.9 ... Company,s expectations. This compares to a net loss for the ... Research and development expenses in the first quarter of 2009 ...
... DNDN ) today announced that management will present at the ... Merrill Lynch 2009 Health Care Conference, The New York ... 9:20 a.m. ET, Deutsche Bank Securities 34th Annual Healthcare ... 2009, 4:35 p.m. ET, Leerink Swann ...
Cached Biology Technology:Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 5
(Date:8/21/2014)... LAWRENCE A study recently published in the journal ... Kansas shows a new role for the protein adenomatous ... second-leading cause of cancer-related deaths in the U.S. , ... of Molecular Biosciences and co-leader of the Cancer Biology ... better part of her career trying to understand the ...
(Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
(Date:8/21/2014)... developed a novel and versatile modeling strategy to simulate ... materials as well as for studying polyelectrolytes, including DNA ... model much larger and more complex polyelectrolyte systems, and ... lead author of a paper on the work and ... Science and Engineering. "This is a big step forward ...
Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... liver disease, extent of tissue damage depends on the balance ... new liver cells. In a significant minority of people who ... form scars. This can progress to chronic liver disease and ... unable to clean blood or produce vital hormones and clotting ...
... a type of cell that can be activated by tissues ... attack our own molecules, cells and organs, UCSF researchers have ... new strategies for fighting a range of autoimmune diseases ... and cells within us as well as for preventing ...
... CHICAGO A low-calorie diet eliminates insulin dependence ... with type 2 diabetes, according to a study presented ... of North America (RSNA). "Lifestyle interventions may have ... patients," said the study,s lead author, Sebastiaan Hammer, M.D., ...
Cached Biology News:The immune system has protective memory cells, researchers discover 2The immune system has protective memory cells, researchers discover 3Restricted calorie diet improves heart function in obese patients with diabetes 2
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... (A) and 36kDa (C) subunits Formulation: ... 500mM NaCl, 60mM 2-mercaptoethanol, 1mM MgCl2, ... and 0.1mg/ml serum albumin Properites: For ... Purification: DEAE chromatography, aminohexyl-agarose and gel ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Biology Products: